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Abstract  
The healing of large bone defects caused by injury or disease remains a clinically 
significant problem, often requiring surgical intervention, as bone is the second most 
commonly transplanted material in the human body after blood transfusion. Therefore, 
there is increasing need for the establishment of alternative treatments such as tissue 
engineered constructs or materials that promote bone healing. To date, for bone 
engineering applications growth factors such as bone morphogenetic protein (BMP) have 
been demonstrated to significantly promote bone regeneration in human patients and 
mesenchymal stem/progenitor cells are very useful tools for enhancing bone 
regeneration. Combinations thereof have shown promising results, though currently they 
remain difficult to be implemented.  
The aim of this thesis was the development of novel strategies to promote the healing of 
bone by recruitment and manipulation of endogenous bone stem and progenitor cells. 
This work relied on previously developed biomimetic hydrogel materials with rationally 
designed, fully defined properties that were optimized towards the culture and 
transplantation of cells as well as the release of growth factors. We designed and applied 
a feasible strategy for precise treatment of molecular modulators in tissue 
progenitor/stem cell populations to improve skeletal manifestations during injury. We 
aimed at dissecting the role of endogenous Mesenchymal Stem cells (MSCs) and the 
recently described Skeletal Stem (SSCs) and Bone Cartilage Stromal Progenitor (BCSP) 
cells combined with osteogenic cues in biomaterials-assisted bone regeneration. 
We demonstrated that these provisional hydrogels, when implanted into bone defects 
serve as traps for cells participating in the process of bone regeneration. We were able to 
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harvest entrapped cells from explanted hydrogels and used them for the characterization 
of healing associated cell populations. We tested different freshly isolated or culture 
expanded cell populations towards their capacity to promote or to participate in bone 
formation and regeneration. We conclude that all the studied subpopulations, MSCs, SSCs 
and BCSPs can be easily accessible cell sources that allow the conception of novel bone 
healing regimen under controlled in vitro and in vivo conditions.  
Taken together, we provide new stem/progenitor cell-based bioengineering tools to 
study factors that promote the healing of bone. These tools will also enable the 
development and testing of smart bone healing implants that are designed to exploit the 
body’s intrinsic capacity to heal by controlling the dynamic and function of tissue 
progenitor/stem cells. We suggest that in the future this approach will likely enable the 
development of novel treatment strategies. 
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Zusammenfassung 
Durch Verletzungen oder Krankheiten hervorgerufene Knochendefekte sind ein 
immenses klinisches Problem und erfordern häufig operative Behandlungen. Nach 
Bluttransfusionen ist Knochen das am zweithäufigsten transplantierte Gewebe. Um die 
Entnahme von körpereigenem Knochengewebe zu vermeiden und die Knochenheilung zu 
unterstützen wurden osteogene Wachstumsfaktoren wie zum Beispiel bone 
morphogenetic protein (BMP) und mesenchymale Stammzellen/Vorläuferzellen sehr 
vielversprechende Hilfsmittel. In den vergangenen Jahren wurde an der Entwicklung von 
künstlichen Knochengeweben mittels «Tissue Engineering» gearbeitet. Obwohl beide 
Faktoren alleine oder in Kombination durchaus vielversprechende Ergebnisse erbracht 
haben, bleibt die Implementierung dieser im klinischen Alltag weiterhin problematisch.  
In der vorliegenden Arbeit beschreiben wir eine neue Strategie, in welcher 
Knochenheilung durch die Rekrutierung und Manipulation von endogenen 
mesenchymalen Stammzellen/Vorläuferzellen unterstützt wird. Wir entwickeln eine 
biomimetische Methode, die darauf abzielt, die natürliche Knochenheilung nachzuahmen 
und zu unterstützen. Da diese Methode auf der Nutzung endogener Zellen beruht, werden 
potentielle endogene Vorläuferzellen untersucht. Folglich untersuchen wir klassische 
mesenchymale Stammzellen (MSCs), sowie kürzlich beschriebene Skelettstammzellen 
(SSCs) und Knochen-Knorpel-Stromal-Vorläuferzellen (BCSP). Wir kombinieren diese 
Zellen jeweils mit osteogenen Wachstumsfaktoren in Biomaterialien und analysieren die 
Knochenheilung. In dieser Arbeit zeigen wir, dass solche Biomaterialien/Hydrogele, wenn 
sie in Knochendefekte implantiert werden, als Fallen für Zellen, die im 
Knochenheilungsprozess eine wichtige Rolle spielen, dienen können. In diesem 
Zusammenhang konnten wir rekrutierte Zellen aus explantierten Hydrogelen erfolgreich 
isolieren und folglich charakterisieren.  Verglichen haben wir frisch isolierte und 
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expandierte Zellen hinsichtlich ihrer Fähigkeit Knochenheilung zu unterstützen oder zu 
begünstigen. Ausserdem haben wir gezeigt, dass MSCs, SSCs und BCSPs gut und einfach 
zu erhalten sind und daher jeweils einen vielversprechenden Zelltyp darstellen, um neue 
Ansätze in der Knochenheilung unter kontrollierten in vitro und in vivo Bedingungen zu 
untersuchen. 
Zusammengefasst legen die Ergebnisse dieser Arbeit nahe, dass diese Methode eine 
Möglichkeit für neue und innovative Knochenimplantate schafft. Wichtig ist dabei vor 
allem, dass die Methode auf der intrinsischen Regenrationsfähigkeit des Körpers beruht. 
Durch die Nutzung endogener Regenerationsprozesse können so neue Strategien für die 
Knochenheilung entwickelt werden. 
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Bone 
Bone is an essential mineralized tissue, which demonstrates a crucial role in maintaining 
mechanical and metabolic function of the body. It has the capacity to adapt to its 
functional environment so that its morphology is developed for the mechanical 
demand. Physiological bone turnover can be classified into two phases: modeling, which 
occurs during development, and remodeling, a process involving tissue renewal 
throughout life (1). 
Bone integrity and function are maintained by an exquisite balance between two major 
cell types involved in the remodeling process: (i) the osteoblasts, arise from mesenchymal 
stem cells, (ii) the osteoclasts, differentiated from hematopoietic stem cells 
(2). Osteoblasts are bone-forming cells, while osteoclasts resorb or break down bone. It is 
essential to maintain a balance between osteoblasts and osteoclasts within the bone 
tissue. 
There are two types of bone tissue: (i) compact and (ii) spongy. Compact bone consists of 
closely packed osteons or haversian systems. The osteon, which consists of a central canal 
termed as osteonic (haversian) canal, is encompassed by concentric rings (lamellae) of 
matrix. Between the rings of matrix, the mature bone cells (osteocytes) are located in 
spaces called lacunae. Small channels (canaliculi) diverge from the lacunae to the osteonic 
(haversian) canal in order to provide alleys throughout the hard matrix. In compact bone, 
the haversian systems are tightly organized to structure the solid mass. Throughout the 
osteonic canals, blood vessels are aligned in parallel to the long axis of the bone. These 
blood vessels are interconnected, by perforated canals, with vessels on the surface of the 
bone. Spongy (cancellous) bone is lighter and less dense than compact bone. Spongy bone 
consists of plates (trabeculae) and bars of bone alongside to small, irregular cavities that 
accommodate red bone marrow. To receive blood the canaliculi connect to the alongside 
cavities, instead of a central medullary canal. The trabeculae bone is arranged in a way to 
provide maximum strength, the trabeculae of spongy bone is aligned with the lines of 
stress and can be realigned according to the direction of stress forces (3). 
Normally bone development occurs through two distinct mechanisms: (i) endochondral 
ossification, in which a cartilage model is gradually replaced by bone, and (ii) 
intramembranous ossification, in which bones are formed directly from condensations of 
10 
 
mesenchymal cells without an intermediate cartilage (Fig. 1) (3). Endochondral 
ossification is the process by which the embryonic cartilaginous model of long bones 
contributes to longitudinal growth and is gradually being replaced by bone. During 
endochondral ossification, chondrocytes proliferate, undergo hypertrophy and die; the 
cartilage extracellular matrix which they construct is then invaded by blood vessels, 
osteoclasts, bone marrow cells and osteoblasts, the last of these deposit bone on remnants 
of cartilage matrix. Unlike endochondral ossification, intramembranous ossification is the 
embryonic development of flat bones, without the participation of cartilaginous tissue. 
Bone formation in fetal stages begins with the aggregation of mesenchyme stem cells to 
form condensations. Within the mesenchymal condensation core, cells differentiate into 
either chondrocytes in endochondral ossification or directly into osteoblasts in the 
intramembranous bone formation pathway. 
Bone is continuously remodeled throughout life and a malfunction between bone 
resorption and bone deposition of this process can emanate bone disease. Osteoblasts and 
osteocytes connected by gap junctions are organized within a cellular network permitting 
the infiltration from the bone surface to the mineral matrix. Osteoclasts, which originate 
from hematopoietic precursors, are modulators for bone resorption correlated to bone 
remodeling.  (4). 
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Figure 1: Representation of bone development during: A) intramembranous ossification B) endochondral 
ossification. A. i) Formation of ossification center by clustering of centrally located mesenchymal cells and 
differentiation into osteoblast. ii) Osteoblasts begin to secrete osteoid and the entrapped differentiate into 
osteocytes. iii) Accumulating osteoid settle between embryonic vessels, resulting in the formation of 
trabeculae bone. iv) Trabeculae is restricted in the inner part as the periosteum thickens, forming the 
woven bone. B. i) Formation of bone collar around the hyaline cartilage. ii) Newly derived osteoblasts cover 
the shaft of the cartilage in a thin layer of bone. iii) Blood vessels penetrate the cartilage as new osteoblasts 
form the spongy bone. iv) The bone thickens and cartilage is restricted at the edges, while the secondary 
center of ossification is formed. v) Remodeling occurs as growth continues, creating the marrow cavity from 
the medullary canal. Hyaline cartilage remains now only in the epiphyseal plates (round edges of the long 
bone) as articular cartilage. (Images adjusted from: http://www.medbullets.com/step1-msk/12021/bone-
formation) 
Bone repair 
Fracture healing is a complex, yet well-orchestrated, regenerative process initiated after 
injury, resulting in optimal skeletal repair and restoration of skeletal function. Bone injury 
is typically correlated with disruption of the integrity of the local soft and vascular tissue. 
During the repair process, the pathway of normal embryonic development is 
recapitulated by the coordinated participation of several cell types (5). Fracture repair is 
a highly complex process that is regulated by physiological, cellular, and molecular 
/genetic factors. The continuing fracture callus remodeling is crucial during the process 
of repair. This includes remodeling of the soft callus (non-specific catabolism), which is a 
largely osteoclast-independent process, and remodeling of the hard callus, which is an 
osteoclast-dependent process (specific catabolism). 
Healing can occur either via direct intramembranous bone formation, if fractures are 
within a proximity range (<25 mm) and well stabilized, or via endochondral bone 
formation if the fracture is non-stabilized or large defects need to be bridged. This damage 
activates of non-specific wound healing pathways that accompany non-skeletal injuries. 
Within the large defects, bleeding is induced in the injury site that evolves into a 
hematoma, which coagulates between and around the injured bone edges forming a 
fibrinous clot (6). Shortly after the first hours of injury, the first cells recruited are 
polymorphonuclear neutrophils, attracted by dead cells and debris and rapidly 
accumulate. Polymorphonuclear neutrophils secrete several chemokines [IL-12+, CC-
chemokine ligand 3 (CCL3; also known as MIP1α)+] that attract longer lived monocytes 
and macrophages (7). The resident macrophage cell population osteomacs, which is 
localized in the endosteal and periosteal surfaces in close proximity to healthy 
unfractured bone, seem to be essential for intramembranous bone formation during 
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fracture healing (8). Early during the inflammatory phase a large number of 
proinflammatory cytokines (IL-6, IL-1, TNF, macrophage colony-stimulating factor 1, 
receptor activator of nuclear factor κB ligand [RANKL]) and members of the transforming 
growth factor (TGF)-β superfamily (bone morphogenetic protein [BMP]-2, BMP-4, BMP-5, 
BMP-6) are released (9, 10). Concomitantly, platelet-derived growth factors (PDGFs) are 
secreted from the platelets, from endothelial cells, vascular cells, and macrophages. In 
addition, angiogenic factors (angiopoetin-1, and, later, vascular endothelial growth 
factor) are released, consequently to the hypoxic conditions generated by the disrupted 
vascularization (11). Revascularization is essential for fracture healing, and angiogenesis 
is required to restore normoxic conditions, abolish debris and supply the injury site with 
cells and mediators (10).  Endothelial cells migrate from periosteal vessels to the bone 
edges and into the hematoma to generate new blood vessels. Blood vessels also allow 
access to an essential source of osteoprogenitor cells, which are suggested to derive from 
pericytes (12). Subsequently, the hematoma is steadily replaced by a granulation tissue, 
which is rich in collagen fibers, cells and invading capillaries. 
Most of bone injuries retain a certain level of mechanical instability and are bridged via 
endochondral ossification. Chondrocytes and fibroblasts form a cartilaginous callus, 
which then undergoes mineralization, resorption and is ultimately replaced with bone 
(13). The callus forms during the late inflammatory phase and intramembranous bone 
formation starts 3-7 days after injury (7). The cells responsible for forming the soft callus 
arise from mesenchymal stem/progenitor cells (MSCs) that proliferate and generate the 
cartilaginous matrix. It is not fully understood where these cells derive, but MSCs most 
likely originate from different sources including periosteum (13, 14), trabecular bone 
(15), surrounding tissues (16), bone marrow (17), and circulation (18). Several cytokines 
and growth factors can induce the mobilization of MSCs to the site of injury. For example, 
stromal cell-derived factor-1 (SDF-1) and its receptor CXCR-4 form an axis (SDF-1/CXCR-
4) which regulates the recruitment of MSCs to the site of injury (19). Moreover, PDGF-BB, 
which is secreted by platelets and preosteoclasts, elevates the proliferation and migration 
of different mesenchymal cell types such as MSCs, pericytes and fibroblasts (20). Hypoxia, 
as well, is an essential factor for mobilization of progenitor cells (21). Chondrocytes 
derived from MSCs proliferate and synthesize a cartilaginous matrix composed of 
collagen-I and -II until the fibrinous/granulation tissue is replaced by cartilage. When 
cartilage can not be further produced, fibroblasts aggregate within the region generating 
13 
 
fibrous tissue. Fibroblast proliferation, chondrocyte differentiation, and matrix 
production are orchestrated by the sequential expression of growth factors including 
TGF-β3 and –β2, PDGF-BB, FGFs, insulin-like growth factor (IGF), and 
growth/differentiation factor 5 (GDF-5) (22, 23). Notably, members of the BMP family 
including BMP-2, -4, -5, -6, -7 also boost cell proliferation and chondrogenesis (24). TGF-
βs and BMPs are mainly secreted by mesenchymal cells, osteoblasts, and chondrocytes. 
While responding to these signals, chondrocytes are able to generate significant amounts 
of collagen II (or collagen X for hypertrophic chondrocytes) (22). 
Following the regeneration process, the primary soft cartilaginous callus is gradually 
resorbed and replaced by a hard bony callus, which allows mechanical rigidness, due to 
its solid interface. At the site of bridging, the soft callus is gradually absorbed, and the 
concomitant revascularization allows the new hard callus to arise. During hard callus 
formation, a process which is typically irregular and under-remodeling, chondrocytes 
undergo apoptosis via hypertrophic formation and calcium release while the newly 
recruited monocytes to the sites differentiate into osteoclast-like cells in order to resorb 
the calcified cartilage (7). The resorption of this mineralized cartilage is organized via the 
signaling cascade comprising M-CSF, receptor activator of nuclear factor κB ligand 
(RANKL), osteoprotegerin (OPG), and TNF-α (22). At the same time, MSCs differentiate 
into osteoblasts and concomitantly replace the connective and granulation tissues 
through intramembranous bone formation. This process is mainly driven by BMPs 
including BMP-2, -3, -4, -5, -6, -7, and -8 (25), which are secreted by hypertrophic 
chondrocytes, osteoblasts and osteocytes (24, 25). Interestingly, this step recapitulates 
the embryological bone development to some extent, with a combination of cellular 
proliferation and differentiation, increasing cellular volume and matrix deposition (22).  
During the final stage of bone repair, the hard callus is replaced by bone tissue with the 
original cortical and/or trabecular architecture. This phase has been termed as secondary 
bone formation (9). Initially, this process involves the converting of irregular woven bone 
callus into lamellar bone, while the standard cortical configuration is ultimately restored. 
A coupled process of orderly bone resorption followed by the formation of lamellar bone, 
drives the remodeling phase while maintaining the process of neo-vascularization. 
Osteoclasts are the key cells involved in the resorption of mineralized bone, adapt a 
polarized morphology and adhere to a mineralized surface. The processes by which 
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osteoclasts resorb bone are acidification and proteolysis of the bone matrix and the 
deposition hydroxyapatite crystals, which are encapsulated within the surrounding zone 
of attachment. The initial process during bone matrix resorption is aggregation of the 
hydroxyapatite crystals by absorption of their ligand to collagen. Then, the residual 
collagen fibers are digested by cathepsins or activated collagenases and the digested 
residues are internalized or transported across the cell and released at the basolateral 
domain. Bone resorption by osteoclasts creates erosive cavities on the bone surface 
known as “Howship’s lacuna” (26). Osteoclast function is regulated by both locally acting 
cytokines and systemic hormones (27). The degradation products are removed through 
vesicles generated from the ruffled border towards the functional secretory domain, 
while osteoclasts are either apoptosed, or restored to the initial non-resorbing form. 
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Figure 2: Representation of the four phases during bone regeneration, including the cellular mechanisms 
and key regulators cytokines and growth factors. A) Inflammatory phase, B) soft callus formation, C) 
mineralization and resorption of the soft callus, and D) bone remodeling. During each phase cytokines and 
growth factors secreted by different cell types. Revascularization and angiogenesis is an ongoing process 
through the inflammatory phase and until the resorption phase (adapted from Mikaël M. Martino (6)). 
BMP = bone morphogenetic protein, FGF = fibroblast growth factor, GDF-5 = growth/differentiation factor 
5, IGF-1= insulin-like growth factor 1, M-CSF = macrophage colony-stimulating factor, OPG = 
osteoprotegerin, PDGF = platelet-derived growth factor, PlGF=placental growth factor, PTH=parathyroid 
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hormone, RANKL=receptor activator of nuclear factor κB ligand, SDF-1=stromal cell-derived factor 1, TGF-
β=transforming growth factor β, TNF-α = tumor necrosis factor α, VEGF= vascular endothelial growth factor. 
Clinical approach 
Large bone defects associated with trauma, tumor, or infection frequently require surgical 
intervention (5, 28). Non-union is the absence of bone union tissue, following a fracture 
that depends on additional treatment/ fixation before healing can occur. The exact time 
length needed to determine whether a fracture is a non-union is not well defined, 
nevertheless, it was suggested at nine months by the United States Food and Drug 
Administration (29). Autologous bone grafts have been used in the treatment of non-
unions defects and currently autograft remains the most commonly used bone graft (28). 
It can originate from a variety of different bone tissue sites, such as the iliac crest, distal 
femur, proximal tibia, fibula, distal radius, and olecranon. However, the clinical most 
common source of autologous bone graft remains the aspiration of cancellous bone 
originated from the iliac crest. Iliac crest bone graft provides optimal osteoconductive and 
possibly osteoinductive properties to the non-union site. Typically, bone tissue can be 
harvested from the iliac crest preserving cell viability and the trabecular architecture. 
Even though the graft cannot provide mechanical stability, it is rapidly incorporated into 
the host healing fracture site (30). Aspirated bone marrow from the iliac crest 
encompasses progenitor cells which can be utilized to induce the osteogenic response of 
the implanted allografts or to restore a non-union defect when applied percutaneously. 
The fibrous tissue interposed between the bone edges ossifies following the injection of 
the bone marrow both in the non-union gap and around the bones. It is yet not fully 
understood whether the bone marrow is responsible to transform the fibrous tissue into 
bone or whether the interposed tissue is converted into bone tissue after the initiation of 
callus formation (obtained from the surrounded bone graft), which blocks micromotion 
at the non-union site and allows union of the gap (28). 
Currently, the transplantation of autologous iliac crest bone graft remains the only 
clinically available graft source that fulfils the criteria of osteogenicity, osteoinductivity, 
and osteoconductivity, while containing viable precursor cells. Its use has resulted in 
reliable union in many clinical studies. However, the risks of infection, rejection, and 
donor site morbidity as well as its limited supply undermine its clinical application and 
remain a serious problem that must be resolved (28, 29). It has been suggested that 5% 
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to 10% of all long bone defects have delayed union, or developed into a non-union (31). 
Apparently, these patients lack or show reduced levels in one or more of the essential 
factors required in fracture healing. Early identification and treatment of impaired 
fracture healing could prevent significant negative impacts, such as prolonged therapy, 
associated with extensive treatment costs for patients (32).  
Bone morphogenetic proteins (BMPs) have been shown to promote the healing of large 
bone defects. The growth factor BMP-2 has been approved by the US Food and Drug 
Administration (FDA) since 2002 and has been clinically established for lumbar spine 
fusion and repair of open tibia fractures (33). In a bone cortex, osteoprogenitor cells, 
osteoblasts, chondrocytes and platelets produce BMPs. After their release, BMPs are 
stored temporary in the extracellular matrix. The regulatory effects of BMPs are tightly 
associated to the target cell type, the stage of the cell differentiation, the local 
concentration of BMPs, along with the interactions with other released proteins. BMPs 
orchestrate a sequence of evolving events resulting in chondrogenesis, osteogenesis, 
angiogenesis and controlled secretion of extracellular matrix (33). A controlled and local 
delivery of BMPs is required in order exert their osteogenic potency. Furthermore, for 
clinical utilization, the short half-life of BMPs needs to be taken into consideration. To 
overcome this limitation several delivery systems have been advanced (22, 34). For 
clinical use of rhBMP-2 (dibotermin alfa), established under the product names 
InductOs® (UK) and InFUSE (US), the active factor is supplied within a bovine collagen 
sponge carrier, allowing relative slow release over time, a combination which was FDA 
approved in 2004 (35). The other clinically used BMP, rhBMP-7, under the product names 
Osigraft® (UK) and OP-1 Putty (US), is administrated in granular form supplemented by 
a bovine collagen carrier. Administration of rhBMP-7 demonstrated more efficient bone 
formation and better bridging the bone edges of defects in comparison to controls 
patients (36).  
Several side effects have been implied with the use of rhBMPs during fracture healing. 
These are associated to the supra-physiological doses, resulting in ectopic bone formation 
and stimulation of cancer cells are being extensively studied. It has been demonstrated 
that RhBMP-2 can induce the formation of pancreatic cancer in a retrospective cohort 
study (37, 38). Side effects of BMP-2 such as ectopic bone formation in non-union 
treatment and acute soft tissue swelling for cervical spine fusions have also been 
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described. However, these effects were associated with the use of very high BMP doses in 
animal studies and varied among species. Ultimately remodeling to the normal bone 
architecture occurred. Apart from the side effects, the costs and the application of rhBMPs 
are also debatable. BMPs are delicate to handle, expensive to manufacture and used in 
supra-physiological doses, resulting in high costs (32, 35). Nevertheless, several studies 
indicate that, the clinical use of both BMP-2 and BMP-7 is still acclaimed, despite these 
costs. Cost reductions for hospitals are mainly associated to shorten the time of surgery, 
as a result of avoiding the bone grafting procedure and faster discharge of the patient. 
(39). Delivering superphysiological doses of BMPs with the aim for enhancement of the 
osteogenic potency might result in the opposite outcome. Recent studies using 
sophisticated biomaterials as BMP carriers show more efficient healing with reduced 
amounts, corresponding more with physiological concentrations (40, 41). Nonetheless, to 
date, BMPs remain a robust treatment to enhance fracture healing with low risk of 
adverse events if properly used. 
Molecular mechanisms mediating bone repair 
Bone injury is associated with destruction of the vasculature resulting in incomplete bone 
healing. Many growth factors, that are expressed during blood vessels formation and 
induced in response to angiogenesis during injury, are believed to play also a significant 
role in the process of bone repair (11). These include members of the FGF, TGF-β, BMP, 
IGF, PDGF, VEGF, hepatocyte growth factor (HGF), erythropoietin, growth hormone, as 
well as parathyroid hormone. 
Recent studies have been conducted to improve understanding of FGF signaling in bone 
formation. FGF-2 has been suggested to be a key-player of cartilage and bone cell 
formation (42, 43). FGF signals through fibroblast growth factor receptors (FGFRs), which 
are important regulators of osteoblastogenesis. Osteoblasts mainly express FGFR1 and 
FGFR2, which are the most crucial receptors in bone-associated cells during the postnatal 
life. Previous studies on humans and mice have indicated the consequences of FGFR 
dysregulation on bone formation (44-47). FGFRs are also important regulators of bone 
growth and development and are expressed differentially in bone and cartilage (45, 48). 
The importance of endogenous FGF2 on bone formation has been emphasized by the 
deletion of FGF2 that leads to decreased osteoblastogenesis associated with an osteopenic 
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phenotype in mice (49). Xiao et al. suggested that endogenous FGF2 drives mesenchymal 
bone marrow stromal cell differentiation into adipocytes or osteoblasts (50). In this 
murine model, endogenous FGF2 was suggested to participate in bone formation both in 
basal conditions and under induction by parathormone (51). Other members of the FGF 
family may also be significant modulators of osteogenesis in vivo. Furthermore, delayed 
ossification has been demonstrated in mice lacking expression of FGF18 indicating that 
FGF18 regulates osteogenesis (52).  
The TGF-β superfamily is comprised of over forty members, including TGF-βs, Nodal, 
Activin, and bone morphogenetic proteins (BMPs) (53, 54) . TGF-β family members are 
expressed in most cell types and are suggested to be involved in tissue morphogenesis 
and differentiation. TGF-β inhibits proliferation of many cell types, such as epithelial and 
hematopoietic cells, and its signaling regulates tumorigenesis (55, 56). The cells response 
to TGF-β is dependent on the cell morphology and physiological environment and differs 
between transcriptional and nontranscriptional regulation . TGF-βs have been 
demonstrated to couple bone construction by osteoblast and bone resorption by 
osteoclast (57, 58).  TGF-β is stimulated by autocrine and/or paracrine effects of 
mesenchymal stem/progenitor cells and plays an important role in their maintenance and 
expansion (59). Bone and cartilage comprise extensive amounts of TGF-β and target cells 
for TGF-β activity. Moreover, TGF-β signaling also induces osteoprogenitor’s 
proliferation, early differentiation, and differentiation towards the osteoblastic lineage 
via the selective MAPKs and Smad2/3 pathways. The cooperation between TGF-β and 
PTH, Wnt, BMP, as well as FGF signaling has been studied. TGF-β1 promotes matrix 
production and osteoblast differentiation and inhibits the osteoblastic secretion of the 
osteoclast differentiation factor RANKL. TGF-β1 thereby indirectly restricts further 
osteoclast formation and induces bone mass (60). TGF-β2 stimulates cranial suture 
closure by promoting osteoprogenitor’s proliferation through the MKK–ERK signaling 
(61), whereas combined delivery of TGF-β3 with an injectable calcium-phosphate matrix 
at the tendon-bone repair site is associated with new bone formation, increased 
fibrocartilage, and improved collagen organization at the healing tendon-bone interface 
(62).  
BMP is currently the most widely utilized inductive factor in bone tissue engineering as 
the US FDA has already approved BMP-2 and BMP-7 for application in fracture and non-
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union management. BMP has been involved in a variety of functions, mainly acting as a 
differentiation modulator of mesenchymal stem cells during endochondral ossification 
(63). The osteoinductive potency of local BMP application have been widely studied in 
various animal species (murine, bovine, and primate). The efficacy of BMP upon bone 
formation have often been correlated with the stimulation of BMP during angiogenesis, 
specifically within bone. BMP secreted in the proximity of the vascularization site has a 
beneficial effect on inducing cells to produce angiogenic factors (64). However, the 
mechanism of BMP augmenting angiogenesis is not fully characterized. Deckers et al. 
showed that BMP induced angiogenesis via the secretion of VEGF from osteoblasts (65), 
whereas other studies revealed that the BMP/Smad signaling pathway is involved in the 
regulation of VEGF transcription, affecting endothelial cells proliferation, migration and 
tube formation (66). 
Growth hormone (GH) and insulin-like growth factor (IGF-1) are essential during skeletal 
growth, puberty and bone health throughout life. GH increases tissue formation by acting 
directly and indirectly on target cells whereas IGF-1 is a critical mediator of bone growth. 
Clinical studies demonstrating the use of GH and IGF-1 in osteoporosis and bone fracture 
healing are depicted (67). GH deficiency in childhood decreases bone mineral density 
(BMD), while GH treatment leads to increases in bone growth and strength in defected 
children (68), IGF-1 is considered essential for longitudinal bone growth, skeletal 
maturation, and bone mass acquisition during development and in the maintenance of 
bone during adult life (69). Osteoblasts are stimulated by IGF secretion resulting in 
enhanced expression of extracellular matrix such as type-I-collagen (70, 71).  
PDGF, which activates angiogenic pathways, is another important osteogenic growth 
factor in fracture healing (72). PDGF is a glycolytic protein released by platelets and other 
cell subpopulations during injury. It stimulates the growth of tissue progenitors in bone 
cartilage, vascular tissue, and connective tissue (72). PDGF-BB/PDGFR-β signaling 
constitutes the principal pathway responsible for pericyte recruitment and attachment to 
the vasculature, their subsequent maturation and potential destabilization and 
detachment (73, 74). Recently, PDGF-BB has gained great interest for bone regeneration. 
It appears that PDGF-BB could play an essential role contributing to the osteoblast 
differentiation process (75). PDGF-BB, in addition to its ability to promote angiogenesis, 
has been reported at sites of injury to promote and mobilize the proliferation of MSCs, 
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osteoblast progenitors and pericytes. In this way, PDGF-BB has been shown to both 
contribute to the osteogenic lineage differentiation and to support stabilization of newly 
forming blood vessels that act to arouse the multistep and multicomponent process of 
new bone formation (75). As a potent mitogen and chemokine, PDGF-BB facilitates tissue 
regeneration by stimulating mesenchymal originated cells such as fibroblasts, osteoblasts 
and chondrocytes. It is also an angiogenic factor, which can upregulate VEGF expression 
(76).  
VEGF is established as a major modulator of angiogenesis, which stimulates endothelial 
cells proliferation, migration and formation of capillary-like structures (77). Although the 
primary function of VEGF is related to vasculature, strong evidence indicates that VEGF is 
also implicated in the survival, activity and recruitment of bone forming cells. Previous 
studies have shown that VEGF directly promotes migration and differentiation in primary 
human osteoblasts (78). VEGF is expressed before blood vessels formation in developing 
bones and its expression is associated with osteoblasts. Furthermore, Peng and colleagues 
showed that the synergistic interaction between BMP-2 and VEGF is partially generated 
by enhanced angiogenesis in the area of bone formation, which leads to increased 
cartilage resorption and augmented mineralized bone formation. These data indicated 
that VEGF plays also an important role in bone development and bone repair beyond its 
angiogenic function (79). Additionally, it was shown that the inhibition of VEGF activity 
disrupts repair of murine femoral fractures and cortical bone defects (80), decreases 
blood flow leading to non-unions in rabbit radial fractures (81). Thus, VEGF activity is not 
only essential for normal angiogenesis, but also for blood vessel invasion which is 
important during tissue repair, suggesting the tight connections between angiogenesis 
and osteogenesis in bone repair may occur through VEGF production (79, 81) 
Cellular Modulators during bone formation 
Extensive investigation has been reported over the previous years to identity an 
endogenous ‘‘skeletal stem cell’’, but it remains not fully comprehensive. Mesenchymal 
stem cells (MSCs) have been widely used in stem cell transplantation, tissue engineering 
and immunotherapy throughout the years.  Scadden determined MSC niches as cell pools 
that can facilitate homeostasis while sustaining MSC populations (82-84). Niches for MSCs 
of different origins can be placed neighboring the vessel walls, on the endosteal regions 
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of trabecular bone, within the interfibrillary areas, or perivascular (85). MSCs migrate to 
injury sites in different animal models, but the underlying mechanisms remain unclear. 
The term MSC was originally conceived in relevance to a common progenitor of a wide 
range of “mesenchymal” (nonhaematopoietic, nonepithelial, and mesodermal) tissues 
(86). Focusing on a combination of in vitro assays and cells surface markers expression 
(87), MSCs exhibit a broad spectrum of lineage potentialities (extending to chondrocytes, 
osteoblast, adipocytes and muscle cells).  
In the past years, bone marrow extracts have been vastly used for treating large bone 
defects in orthopedic surgery (17, 82). Periosteum, as well, has been utilized as a source 
of MSCs (14, 88). Other studies have investigated the role of pluripotent mesenchymal 
cells from vessel walls, pericytes, during bone healing, since ineffective angiogenesis 
marks non-union defects (89, 90). They demonstrated that pericytes can be induced 
towards expression of chondrogenic and adipogenic markers under defined culture 
conditions. Muscle has also been utilized as cell source for bone repair (91), but harvesting 
is limited and the cells show restricted capacity during multilineage differentiation. The 
hypothesis of circulating MSCs during bone healing remains questionable (92). Sources of 
MSCs, previously used, include adipose tissue, umbilical cord blood, dental tissues, tendon 
and skin (15, 93-97). Numerous studies have demonstrated that MSCs undergo osteogenic 
lineage by differentiation and can form mature osteoblasts (12, 98). In addition, many 
other studies have reported that the delivery of recruitment factors together with a 
sufficient quantity of MSCs within the microenvironment of the injury site is effective for 
healing (99-101). The recruitment of the stem cells which are involved in callus 
condensation is related to the extent and the type of defect (102-104). Another parameter 
that should be taken into consideration is stability during fixation and immobilization of 
the damaged tissue, which will also influence the lineage restriction of skeletogenic stem 
cell to differentiate into either chondrocytes or osteoblasts, with more-extensive cartilage 
tissue formation associated with less stability for chondrocytes, and increased stability 
due to bone tissue in favor of osteoblasts (104). 
However, despite the fact that the MSC populations have been extensively employed in 
defining immunophenotypes and in vitro clonogenic and multilineage potential (87), their 
in vivo function and anatomical localization has not been rigorously characterized (105). 
Only recently, it was shown that MSCs in multiple human tissues reside in perivascular 
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niches and that prospectively isolated CD146+ human bone marrow-derived SSCs give 
rise to bone when transplanted in the absence of osteogenic signals (12, 106, 107). These 
cells can self-renew upon serial transplantation, fulfilling a key criterion of bona fide stem 
cells. Analogues to CD146+ human bone marrow SSCs, murine SSCs have been isolated 
from the bone marrow by selecting for Sca1 (108), Nestin (109), Mx1 (82), or Leptin 
receptor expression (110). Furthermore, by lineage mapping of developing long bones, 
based on the expression of AlphaV (αV integrin) for the osteogenic lineage, a mouse SSC 
population has been identified, which when transplanted beneath the renal capsule, can 
give rise to osteogenic, chondrogenic and stromal tissue (111).  Chan et al. suggested that 
skeletogenesis may proceed through lineage-restricted progenitors selected upon 
developmental hierarchy a process similar to hematopoiesis. The SSCs (CD45-TER119-
Tie2-AlphaV+Thy-6C3-CD105-CD200+) initiate skeletogenesis by producing a hierarchy of 
increasingly fate restricted progenitors, such as Bone Cartilage Stromal Progenitors 
(BCSP) (CD45-TER119-Tie2-AlphaV+Thy-6C3-CD105+) (111). His research indicates that 
the skeletogenic progenitors are diverse, with specific cell-surface profile markers and 
skeletal tissue fates, resembling the hematopoietic progenitor cells that differentiate into 
the various blood cells.  
Collectively, the ideal stem cell source for fracture repair should be easily accessible, 
isolation should be conducted without being time and labour-intense and cells should be 
rapidly expandable by in vitro culture, while survival and integration within the host bone 
tissue should be adequate, showing no tumourigenicity or site morbidity effects. 
Bone Engineering 
Bone has the capacity to regenerate without the formation of scar tissue, but only if 
certain conditions are met. These conditions are related to: (i) the size of the defect, (ii) 
the location and vicinity to an efficient vascular bed to allow vasculature and (iii) the 
mechanical stability of the defect. The combination of osteoconductive biomaterials with 
osteoinductive factors and stem/progenitor cells holds a great promise. Although, we still 
do not fully understand optimal combinations, doses and release kinetics, making them 
hard to be implemented in safe and clinically effective approaches. 
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Bone tissue engineering is a promising alternative strategy for inducing tissue 
regeneration and has thus attracted considerable attention (112, 113). The capacity of 
bone to self-renew has been an advantageous paradigm of nature to assist and inform 
tissue engineering strategies towards generating new options of treatment. Conventional 
tissue engineering combines of biomaterials, appropriate bioactive molecules, and cells, 
which may be limited due to long-term in vitro culture for the formation of new bones, the 
high cost of cell isolation, proliferation and maturation or differentiation, as well as the 
risk of pathogens contamination (114).  
Alternatively, the principle of in situ bone tissue regeneration involves target-specific 
scaffolds incorporated with bioactive molecules and implanted in vivo. The sustained 
release of the bioactive cues deciphers the body’s own regenerative capability. 
Consecutively, this enhances the mobilization of tissue-specific host stem/progenitor 
cells, promotes proliferation and differentiation of these recruited cells into the targeted 
cell types and reconstructs functional tissues allowing the damaged tissue to be 
regenerated without the need for cell transplantation. Biomaterials and scaffolds specific 
for bone, either alone or in combination with bioactive osteogenic modulators, are 
directly introduced to the defect regions, to recruit circulating host stem cells in situ, 
aiming to induce the osteogenic differentiation of tissue progenitors towards bone 
regeneration (115).  Biomaterials for in situ tissue regeneration (BITR) must possess 
some basic characteristics such as: (i) suitable microstructures and mechanical 
properties, (ii) proper surface topography and chemistry, (iii) biodegradability and non-
cytotoxic degradation products, and (iv) simple and cost effective manufacturing 
technology (116). 
Biomaterials comprises a key element in bone tissue engineering and provides a three-
dimensional (3D) scaffold to support cell growth and the formation of the extracellular 
matrix (ECM) (116). Scaffolds typically consist of a solid support structure with an 
interconnected pore network, while matrices are often hydrogels containing 
encapsulated cells. Both forms must support cell colonization, proliferation, 
differentiation and migration. Additionally, they should maintain appropriate 
physicochemical properties (such as stiffness, strength, biodegradability, surface 
configuration) that are essential for tissue formation and have an application in sustaining 
and responding to mechanical stresses (117). The site of implantation along with the size 
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and shape of the implant can affect in vivo degradation. Assessment of the 
biodegradability of engineered constructs in vivo is still its infancy, with the main focus 
being on the local effect of dissolution products from scaffold degradation on 
osseointegration and bone formation. Part of the problem is the lack of long-term follow-
up studies on these materials when used in vivo in clinical settings (117). Most of these 
biomaterials are not in widespread clinical use, reducing the power of any follow-up study 
to determine the rate of degradation in humans.  
Synthetic and natural polymers are popular biomaterials due to the vast diversity of their 
properties and their bioactivity (118). Natural polymers were among the first 
biodegradable scaffold materials to be used clinically, cause of their preferred overall 
interactions with various cell types, and lack of an immune response. Natural polymers 
such as fibrin, collagen, gelatin, alginate, hydroxyapatite and β-tricalcium phosphate are 
currently used both alone and combined (119). While these biomaterials have shown to 
possess to certain extent osteogenic capacities, often they are not sufficient to promote 
bone healing. Indeed, optimal bone regeneration not only depends on an osteoconductive 
matrix and on mechanical stability, but also on osteoinductive modulators and osteogenic 
cells (120, 121). However, synthetic polymers despite the potential for an immune 
reaction or toxicity when combined with certain polymers, were later recognized to have 
lower cost and with the advantage to be tailored (122). Among the synthetic polymers, 
poly(glycolic acid) (PGA), poly(lactic-co-glycolic) acid (PLGA),  poly(L-lactic acid) (PLLA) 
and poly(caprolactone) (PCL) are currently the most widespread for the creation of 3D 
scaffolds (123). These polymers have also been utilized in combination with natural 
polymers to improve adverse effects related to hydrophilicity, cell attachment, and 
biodegradability. These synthetic scaffolds offer a minimalist approach to develop models 
in a fully controlled and reproducible manner, enabling the study of biological and cellular 
processes on a “blank slate”. Moreover, the scaffold can be functionalized using ligand 
specific domains such as protein modulators that assist in enhancing cellular responses. 
Therefore, common strategies to response into better or faster healing are currently 
issued by delivering osteoinductive growth factors and/or stem/progenitor cells through 
osteoconductive biomaterials.  
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PEG (poly (ethylene) glycol) hydrogel for bone tissue engineering 
Many laboratories are using synthetic materials such as PEG to mimic stem cell 
environments. Previously in our lab, an enzymatically crosslinked PEG-based hydrogel 
termed TG-PEG was developed. TG-PEG is crosslinked by the transglutaminase factor XIII 
(FXIII) recapitulating the end of the blood coagulation cascade. In TG-PEG, 8-arm-PEG-
vinylsulfone molecules are functionalized with two peptides via a Michael-type addition 
reaction. These peptides, containing lysine or glutamine residues, act as substrates for 
FXIIIa crosslinking (124). PEG-based hydrogels are inert and highly reproducible. Their 
mild crosslinking conditions maintain the viability of encapsulated cells and allow for 
ECM deposition. This hydrogel has proven its potential to allow the recreation of 
environments similar to those encountered by cells in nature. 
The ECM-mimicking structure does not only give an adequate network for cell survival 
but also enables stiffness and degradability variation for optimal cell behavior. 
Furthermore, its chemical structure permits the addition of cell instructive signals to its 
backbone, allowing the flexible and independent variation of multiple parameters 
towards the reconstruction of a native-like 3D microenvironment (125). Simultaneously 
with the hydrogel crosslinking, growth factors, adhesion peptides and other biological 
entities can be incorporated in a highly controlled manner (126). Adhesion sites such as 
RGD are added following the same principles. This amino acid sequence combined with a 
MMP-sensitive domain, present in the linker-peptide, is essential for allowing cell 
survival, spreading and migration. Lastly, these hydrogels allow for facile tailoring of 
properties such as stiffness, degradability, and cell-adhesion (127, 128). 
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 Figure 3: Formation of TG-PEG hydrogels by crosslinking two multiarm PEG peptide conjugates (n-PEG-
MMP sensitive P-Lys and n-PEG-Gln) in combination with a cell adhesion peptide (TG-Gln-RGD) catalyzed by FXIII 
transglutamination. 
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Motivation and overall goal 
Previously described clinical studies, based on strategies promoting the inherent 
(limited) capacity of bone to regenerate, rely on the delivery of osteoinductive factors 
such as BMPs (33) or on the transplantation of autologous bone marrow-derived stem 
cells BM-MSCs (28). MSCs were shown to promote bone regeneration in preclinical trials, 
however achieving statistically significant efficacy in clinical trials has been challenging 
(129). This is most likely due to variation in stem/progenitor cell selection criteria and 
because the cells’ regenerative capability cannot readily be controlled once transplanted 
(2). 
While it is well known that bone has an inherent capacity to regenerate, this potential has 
not been fully explored to date. This is mostly due to the still incomplete knowledge on 
cellular and molecular mechanism modulating bone regeneration (104). One of these 
missing gaps until very recently has been the lacking information on both the phenotypic 
properties of skeletal stem cells and the anatomic localization of their niche (105, 107). 
Only very recently cell populations, which likely comprise skeletal stem and progenitor 
cells have been characterized and isolated (109-111). However, this newly established 
knowhow so far has not been implemented into therapeutic approaches, which would 
magnify the body’s inherent regenerative capacity. 
As a basis for this project, we employed previously developed biomimetic PEG-hydrogels, 
which can be tailored towards specific biological applications by the independent 
variation of physical and biological properties (124, 127). In previous studies, these 
provisional materials were optimized toward the induction of bone regeneration in a 
murine craniotomy model (128, 130). Such materials which contained or did not contain 
growth factors were implanted in murine calvarial defects. Our data indicated that tissue 
stem/progenitor cells were able to infiltrate BMP-2 releasing hydrogels where they 
differentiated into bone forming cells and participated in bone healing. The overall goal 
of this thesis was to develop treatments that by mobilization or transplantation of skeletal 
stem and progenitor cells could promote the BMP-2-mediated murine calvarial bone 
regeneration. 
29 
 
Specific aims 
Specific aim 1: To establish a model for recruitment, migration and differentiation 
of tissue stem/progenitor cells during orthotopic bone healing. The aim of this study 
was to identify healing associated stem/progenitor populations and to determine factors 
that by promoting their mobilization will enhance BMP-2 mediated bone regeneration. 
We focused on establishing an in vivo model, which allows the trapping of cells that 
participate in the healing murine calvarial bone defects. Applying this biomimetic ò cell-
trap ó , we aimed at identifying cell populations that fulfil both in vitro  and in vivo criteria 
of endogenous skeletal stem/progenitor cells and factors that promote bone regeneration 
by the recruitment of identified skeletal stem/progenitor cells. 
Specific aim 2: To investigate the role of SDF- s=                                    
elucidating biomolecule governed MSC homing in bone regeneration in vivo. The 
aim of this study was to investigate if biomaterials-delivered SDF-1 = and BMP-2 can 
promote the regeneration of non-union bone defects. We focused on determining if SDF-
1= can facilitate recruitment of tissue stem/progenitor cells at the early stage of bone 
injury . We employed the earlier established (specific aim 1) PEG-hydrogel approach for 
determining the role of SDF-s=             -2 on the recruitment of healing associated 
skeletal stem/progenitor and their potential contribution to the healing of non-union 
bone defects.  
Specific aim 3: To determine the participation of SSCs and BCSPs, their induction 
and expansion assessed in orthotopic bone heling established model. The aim of this 
study was to investigate if recently identified Skeletal Stem Cells (SSCs) and Bone 
Cartilage Stromal Progenitors (BCSP) (111) participate in biomaterials induced bone 
regeneration and if their enrichment could promote bone regeneration. By applying the 
previously established biomimetic PEG-hydrogel approach (specific aim 1); we aimed at 
elucidating the SSCs and BCSP osteogenic potency both in vitro and in vivo after either 
prospective isolation or after cell culture expansion. 
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Figure 4: Conceptual schematic of herein thesis. 
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Chapter III The role of biomaterials delivered SDF-1α 
in skeletal stem cell homing and bone regeneration 
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Abstract 
SDF-1α expression is considered as one of the signals to induce the migration of stem and 
progenitor cells to sites of tissue repair and regeneration.  In this study, we aimed at 
determining if biomaterials delivery of SDF-1α and BMP-2 can facilitate recruitment of 
tissue stem/progenitor cells and bone formation. Our results indicated that PEG-
hydrogels-based dual delivery of BMP-2 and SDF-1α induced the augmentation of native 
bone more efficiently than delivery of the individual factors. This resulted in induced bone 
augmentation, demonstrating a potential osteogenic differentiation stimulus upon the 
periosteal cell layer. Furthermore, our findings indicated that PEG-hydrogel delivered 
SDF-1α in non-union bone defects of the murine skull is unable to promote BMP-2-
mediated bone regeneration as well as recruitment of Sca1+ SSCs. Taken together, our 
research suggests that during bone healing SDF-1α might have distinct functions in the 
recruitment, proliferation and differentiations of different cellular fractions.  
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Introduction 
Bone morphogenetic protein (BMP) has been shown to be a growth factor that can 
promote the formation of bone. However, as sole treatment BMP is required in 
supraphysiological dose, restricting its clinical applicability. The mobilization of skeletal 
stem and progenitor cells is considered as an important concomitant parameter 
influencing the efficiency of bone regeneration and could be critical in the regeneration of 
non-union bone defects (1). Current data suggest that stromal cell-derived factor-1 (SDF-
1 or CXCL12) and its G-protein-coupled main receptor CXCR-4 form an essential axis 
(SDF-1/CXCR-4) for the recruitment of MSCs expressing CXCR-4 during endochondral 
fracture healing (2) and the acute phase of bone repair (3). Consistent with this, treatment 
with an anti-SDF-1 antagonist or genetic depletion of SDF-1 or CXCR-4 resulted in 
impaired fracture healing (4). Additionally, hypoxia has been shown to enhance CXCR4 
expression in association with HIF-1α (5, 6), which might be a possible mechanism leading 
to the upregulated SDF-1 expression in the periosteum and at the boarders of fracture 
sites (7). Furthermore, perturbing the SDF-1/CXCR4 signaling axis in primary human and 
mouse bone marrow derived MSCs interrupt their BMP2-mediated differentiation 
towards osteogenic lineage (3). Together these recent findings indicate that SDF-1 in 
addition to mobilizing MSCs to sites of tissue regeneration could have a role in modulating 
their lineage specific differentiation.  
Applying the chemoattractant and osteogenic properties of SDF-1 and BMP-2, 
respectively, several studies have already investigated their combination towards bone 
regeneration (8-13). Hwang and colleagues demonstrated that treatments with collagen 
scaffold sequentially releasing SDF-1 followed by BMP-2 exhibited more robust bone 
regeneration as compared to simultaneous treatment with both BMP-2 and SDF-1 (9). 
These results indicate that SDF-1 might improve the mobilization and local enrichment of 
MSCs, which can subsequently undergo osteogenic differentiation in response to low 
doses of BMP-2. They further suggest that the SDF-1/CXCR4 axis is of minor importance 
in promoting osteogenic signaling. However, in another study, the osteogenic induction 
by suboptimal concentrations of BMP-2 was potentiated in a dose-dependent manner by 
SDF-1β and inhibited by blocking of CXCR4/SDF-1 signaling axis, suggesting a role of SDF-
1β in BMP-2 osteogenic signaling (8). 
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Novel fibroin -nanohydroxyapatite scaffolds comprising silk fibroin microspheres with 
encapsulated BMP-2 and physically adsorbed SDF-1 resulted in enhanced bone 
regeneration when compared to BMP-2 or SDF-1 only (12). Finally, in vivo experiments 
by Higashino et al. suggested that SDF-1 enhanced BMP-2-induced mobilization of 
circulating bone marrow-derived osteoprogenitor cells resulting in increased 
osteoprogenitor differentiation and ectopic bone formation in collagen discs. 
Unfortunately, in this study neither direct effect of SDF-1, SDF-1 release kinetics after 
implantation  nor recruitment of local skeletal stem/progenitor cells were evaluated (10). 
Therefore, the aim of this study was to determine if biomaterials-delivered SDF-1 can 
stimulate the recruitment of local bone stem/progenitor cells and by this promote the 
BMP-2-mediated regeneration of non-union bone defects. To dissect biomaterials and 
growth factor-mediated effects during the regeneration of bone we have earlier employed 
synthetic poly (ethylene)glycol (PEG)-based hydrogels that comprise the cell adhesion 
site RGD as well as MMP-1 sites. These provisional PEG-based materials have previously 
been optimized towards bone regeneration and have shown excellent properties when 
used for the delivery of BMP-2 (14, 15). 
Herein we show evidence that combined fast delivery of SDF-s=  and BMP-2 from PEG-
hydrogel promotes the augmentation of native bone more efficiently than BMP-2 or SDF-
s= monotherapy. Interestingly, this effect could not be reproduced in a non-union bone 
defect model using PEG-hydrogels or collagen sponges as growth factor delivery tools. 
Additionally, while BMP-2 induced the mobilization of skeletal stem/progenitor cells, 
SDF-s= had not detectable effect on these cells. Collectively, our data indicate that SDF-
s=; instead of promoting the mobilization of skeletal stem/progenitor cells, supports the 
induction of periosteal cells and enhances their osteogenic potential. 
Results 
SDF-w= does not boost the BMP-2-mediated  regeneration of non -union bone defects 
To determine if SDF-s=  can promote BMP-2-mediated healing of non-union bone defects, 
craniotomies were performed in murine parietal bones and defects were left untreated to 
enable the formation of a fibrous tissue inside the bone defects. 4 weeks after craniotomy, 
skin was cleaved and 11µl PEG-based biomimetic implants containing SDF-s= s  µ g), low 
41 
 
dose BMP-2 (0.2 µg) or a combination thereof were placed on top of the defect covering 
fibrous tissue layer. 4 weeks later the calvarial bones were harvested and bone formation 
was assessed by micro-CT and histology (Figure 1A, B). We show that neither the delivery 
of the individual factors nor the combined delivery promoted the regeneration of non-
union defects (Figure 1B). Since the implantation of the scaffolds was achieved with a 2-
step operation and the connective tissue generated within the defects was not removed, 
this led to an instable positioning and shifting of the hydrogels after implantation onto the 
native bone. Interestingly, the native bone was augmented by treatment with hydrogels 
released SDF-1α and BMP-2, while solo treatment with BMP-2 and SDF-1α had no impact 
in bone regeneration. SDF-1α releasing hydrogels were fully degraded, while control 
hydrogels and BMP-2 releasing hydrogels remained intact.  (Figure 1B, indicated by dash 
line). 
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Figure 1. Assessment of dual delivery of BMP-2 and SDF- s=                                         ä  A) 8-weeks 
post-craniotomy and 4-weeks post-implantation bone formation was assed ex situ. Representative top 
views of 3D surface rendered micro-CT measurements (scale bar: 1 mm, left panel). B) H&E staining of 
                                  Æ                                                                                                     ª  trr  J Æ                 
indicating the remaining volume of the hydrogels in a translocated position. C) Quantitative assessment of 
43 
 
generated bone volume, connectivity and % coverage of the defected area. Data is depicted as mean – SD, n 
= 6. One-                             ï                    Æ                       ä  
PEG-based hydrogels loaded with BMP-2 and SDF-w=  fails to boost bone formation on 
orthotopic bone model  
To confirm if the absence of healing in non-union defects was due to shifting of the 
hydrogel implants we next aimed at immobilizing hydrogels at the site of application by 
the use of fibrin as a provisional gluing material.  Again, to determine if dual delivery of 
BMP-2 and SDF-s=                                             -size murine calvarial defects, PEG-
based biomimetic hydrogels fast releasing 1µ g SDF-s=Æ  rät µ g BMP-2 and combination of 
0.2µ g BMP-2 and 1µ g SDF-s=                                  ä  v               -implantation the 
calvaria were harvested and bone formation was assessed by micro-CT and histology 
(Figure 2A, B). Histologies indicate that indeed the hydrogel implants reproducibly 
remained in the correct implantation position. Consistent with the previous experiment, 
the delivery of individual  factors as well as combinations of BMP-2 and SDF-s=              
promote bone regeneration within the defect area (Figure 2B, C). These results suggest 
that the dual treatment of BMP-2 and SDF-s=       not induce bone formation within the 
defected region. 
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Figure 2. Assessment of dual delivery of BMP-2 and SDF-1α in orthotopic bone healing in 2-step operations. 
A) 8-weeks post-craniotomy and 4-weeks post-implantation bone formation was assed ex situ. 
Representative top views of 3D surface rendered micro-CT measurements (scale bar: 1 mm, left panel). B) 
H&E staining of coronal cross sections, asterisks indicating the remaining volume of the hydrogels (scale 
45 
 
    ª  trr  J ä  C) Quantitative assessment of generated bone volume, connectivity and % coverage. Data is 
depicted as mean – SD, n = 4. One-                            ï                    Æ                      ä  
Effect of dual delivery BMP-2 and SDF-w=                                                        
calvarial defect mediated by collagen sponges  
The healing of bone defects can be altered by selective synthetic hydrogel specific cell 
adhesion and migration properties as well as potentially altered growth factor binding as 
compared to native provisional matrices (14).  To evaluate if observed healing responses 
are due to our synthetic hydrogels, we utilized absorbable collagen sponges (ACS, 
Lyostyptfi) . To confirm the synergetic effect of BMP-2 and SDF-s=                    
described (8, 9, 16, 17) with collagen as a carrier, ACS disc-shaped were soaked in 1µg 
SDF-s=Æ  rät  `        -2 and combination of 0.2µg BMP-2 and 1µg SDF-s=  and were 
delivered in murine critical -size defects. 4 weeks post-implantation the calvarial bones 
were harvested and bone formation was assessed by micro-CT and histology (Figure 3A, 
B). ACS demonstrated enhanced bone formation within all  the different treatments, even 
under SDF-s=             alone, suggesting that the collagen carrier by itself can augment 
bone formation, masking the demonstrated osteogenic potential of the BMP-2 and SDF-
s=ä   
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Figure 3. Assessment of dual delivery of BMP-2 and SDF-1α upon murine calvarial bone. A) 4-weeks post-
implantation bone formation was assed ex situ. B) Representative coronal cross sections of 3D surface 
rendered micro-CT measurements (scale bar: 1 mm, left panel) C) Quantitative assessment of generated 
bone volume, connectivity and % coverage. Data is depicted as mean ± SD, n = 4. One-way ANOVA 
Bonferroni’s post hoc test, * p < 0.05. 
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Onlay bone augmentation of murine calvarial bone after synergetic effect of BMP -2 
and SDF-w=   
To investigate if the dual delivery of BMP-2 and SDF-s=                                     
upon triggering the periosteal cells to undergo the osteogenic lineage, PEG-based 
biomimetic hydrogels fast releasing 1µ g SDF-s=Æ  rät µ g BMP-2 and combination of 0.2µ g 
BMP-2 and 1ug SDF-s=             Æ                Æ                                          ä   v          
post-implantation the calvarial bones were harvested and bone formation was assessed 
by micro-CT and histology (Figure 4A, B). Here, we show that combined delivery of low 
dose BMP-2 (0.2 µ g) and SDF-s= s  µ g) augments bone formation upon treatment (Figure 
4B). These findings indicate that the dual treatment of BMP-2 and SDF-s=             
periosteal cell layer of the native calvarial bone resulted in induced bone augmentation, 
demonstrating a potential osteogenic differentiation factor of the periosteal cells upon 
stimulation.  
Figure 4. Assessment of dual delivery of BMP-2 and SDF- s=                                        ä   A) 4-weeks post-
implantation bone formation was assed ex situ. Representative coronal cross sections of 3D surface 
rendered micro-CT measurements (scale bar: 1 mm, left panel). B) H&E staining of coronal cross sections, 
                                                                             ª  trr J ä   
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Injury -associated Sca1+SSCs recruitment under SDF -w=                                  
fracture site  
More recent studies indicate that SDF-s=                                                             
stem cells, progenitor cells and organ-specific homing through its interaction with CXCR4 
(18, 19). To determine whether SDF-s=                                   ent of earlier 
described Sca1+ SSCs (Sca1+CD31-CD45-Ter119-CD90-6C3-, Chapter II) into murine 
critical -size calvarial defects biomimetic PEG-based cell-traps containing 1ug of fast 
realizing SDF-s=                                                      cell-infiltration was allowed 
to take place for 8-days. As control served empty implants or PEG-hydrogels loaded with 
0.2ug BMP-2. Isolation was accomplished by enzymatic dissociation and staining for 
fluorescence activated cell sorting (FACS) (Figure 5A). We show that the recruitment of 
injury -associated Sca1+SSCs is significantly induced by BMP-2 stimulation as compared to 
control implants (Figure 5B). However, in response to SDF-s=                                
recruitment of Sca1+ SSCs was observed. This data suggests that in our PEG-hydrogel 
implants BMP-2 could enhance the mobilization of Sca1+SSC, while SDF-s=      
ineffective.  
 
Figure 5. Sca1+ SSCs recruitment in a healing fracture site entrapped in PEG-based hydrogels. PEG-
based hydrogels fast-releasing 0, 1ug SDF- s=        rät           -2 were implanted in murine critical-size 
calvarial defects and were allowed to be infiltrated from cells for 8-days. A) Sca1+SSCs cells were 
characterized by FACS. B) Quantitative assessment of recruited injury-associated Sca1. Data is depicted as 
mean – SD, n = 6. One-                              ï                        p < 0.05. 
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Discussion 
In this study, we present data indicating that SDF-1α can promote the BMP-2 mediated 
augmentation of native, uninjured bone. Our current data suggests that this effect is due 
to the induction of periosteum-derived stem/progenitor cells rather than the recruitment 
of Sca1+ SSCs from bone marrow or perivascular origin. 
We employed an earlier established (Chapter II) PEG-hydrogel cell-trap approach for 
determining the role of SDF-1α and BMP-2 on the recruitment of healing associated Sca1+ 
SSCs and their potential contribution to the healing of non-union bone defects. The used 
soft (250Pa) biocompatible hydrogel materials were designed to be biodegradable, and 
to provide the cell adhesion site RGD, which are minimal criteria to allow the infiltration 
of healing-associated cells. Due to their hydrophilic and non-fouling properties, these 
hydrogels, in absence of engineered growth factor affinity sites, do not significantly bind 
and retain admixed native growth factors. These hydrogels therefore offer the advantage 
of evaluating cytokine functions under fully controlled environmental conditions and 
enable the dissection of individual experimental parameters.  
Non-union bone defects remain one of the clinical challenges that needs to be overcome. 
In such defects a fibrous tissue is formed, which under normal circumstances will persist 
and even prevent a later initiation of natural bone healing (1). In order to imitate non-
union defects, herein we established a critical-sized defect in the parietal bone of the skull 
and allowed the healing to occur for four weeks, enabling the formation of a fibrous tissue 
across the bone defect and the demission of the operation induced inflammatory 
response. We reason that in this model the microenvironmental conditions are not in 
favor of bone formation and that the initiation of bone formation will critically depend on 
the recruitment or induction of skeletal stem/progenitor cells. In this model, we showed 
that the dual delivery of BMP-2 and SDF-1α from PEG-based matrices could not induce 
bone healing. In contrast, when hydrogels containing low concentrations of BMP-2 and 
SDF-1α were placed upon the periosteum of intact bones, new bone structures were 
initiated on top of this mature bones. Our data indicate that the formation of new bone 
was more pronounced in presence of co-treatments compared to solo BMP-2 treatment, 
suggesting that during bone healing SDF-1α might have a supportive role on the 
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recruitment, proliferation and differentiation of osteogenic cellular fractions upon 
treatment of native calvarial bone.  
In contrast to PEG hydrogels, collagen, one of the main classes of structural extracellular 
matrix (ECM) proteins exhibits multiple inherent biological properties such as variable 
cell-binding sites, biodegradability making it an excellent substrate for the delivery of 
growth factors and cytokines (20, 21). In this study, we demonstrated that the delivery of 
both SDF-1α and BMP-2 from collagen matrices was superior to their delivery from PEG 
hydrogels. A difference which can be due to multiple reasons such as a change in cellular 
infiltration, selective integrin-dependent infiltration of cell populations, rate of growth 
factor delivery, rate of biomaterial degradation or changes in growth factor integrin co-
signaling. As especially in collagen matrices these effects are highly interrelated they 
cannot be easily dissected and would clearly need to be evaluated in more detail. 
BMP-2 has long been established as a factor that induces bone formation by the 
differentiation of mesenchymal stem as well as bone progenitor cells (1). However, very 
recent studies now provide evidence that BMP-2 could also promote the induction and 
mobilization of SSCs (22). In contrast, the SDF-1α/CXCR4 axis has been described to be 
involved in the recruitment of multiple stem and progenitor cell types including 
hematopoietic stem cells, endothelial progenitor cells, and healing associated stromal 
cells (19, 23). Only recently it has been suggested that SDF-1α could be employed to 
improve the recruitment of MSCs and consequently to boost the regeneration of bone in 
presence of BMP-2. In first preclinical trials, data regarding the role of biomaterials 
delivered SDF-1α in BMP-2-mediated healing of bone defects were contradictory. While 
in some studies SDF-1α promoted BMP-2 induced bone formation, in others studies the 
effect was not significant or even inhibitory (8, 9). To further explore a potential in vivo 
role of SDF-1α in mediating the migration of Sca1+ SSCs to healing bones, here fast 
releasing SDF-1α hydrogels were implanted in murine calvarial critical-sized defects, 
employed to entrap all healing participating cells and characterize various cell 
populations by FACS at 8 days of treatment. Our data indicate that consistent with the 
literature BMP-2 stimulated, while SDF-1α had no effect in the number of Sca1+ SSCs 
present in the healing bone defects. Interestingly, after 8 weeks of implantation SDF-1α 
releasing hydrogels were fully degraded and replaced by recruited cells, while control 
hydrogels and BMP-2 releasing hydrogels remained intact. These data indicate that the 
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mobilization and proliferation of cells distinct from SSCs were induced by SDF-1α 
treatment.  
In this study, the focus was on examining SDF-1α effects on Sca1+ SSCs recruitment and 
bone formation at constant concentrations, therefore concentration dependent effects 
cannot be excluded. In fact, a very recent study showing that improved bone healing was 
only obtained if SDF-1α and BMP-2 were delivered in a controlled and sequential manner 
implies that attention should be paid to the exact mode of delivery (12, 17). Although 
herein employed hydrogel can be engineered towards controlled delivery of growth 
factors and cytokines both factors SDF-1α and BMP-2 were simply admixed to the 
hydrogel, resulting in passive diffusion. Therefore, to fast release kinetics of SDF-1α and 
rapid loss of the stem cell recruitment activity could be a reason for the failure of 
combined treatment to improve healing of bone defects. Further evaluations of growth 
factor release rates under in vivo conditions, as well as using refined growth factor release 
properties would be required. Additionally, to fully understand SDF-1α-mediated cellular 
and molecular mechanisms contributing to BMP-mediated bone regeneration further 
investigation should be conducted.   
Conclusions 
While the role of SDF-1α signaling in the complexities of in vivo bone formation remains 
to be fully understood, we demonstrated that dual delivery of BMP-2 and SDF-1α could 
lead to bone augmentation upon treatment of native calvarial bone via PEG-based 
hydrogel application. In this study, the release of growth factors has not been engineered 
and in vivo release kinetics have not been determined. Therefore, it remains unknown if 
dual delivery of BMP-2 and SDF-1α was ineffective due to the mode of delivery or due to 
the inability of healing associated to stem/progenitors respond to the provided signals.  
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Materials and Methods 
Formation of scaffolds: TG-PEG hydrogels were formed by FXIIIa cross-linking of 
equimolar blends of two eight-arm PEG macromers (8-PEG-MMPsensitive-Lys and 8-PEG-
Gln) as previously described (24, 25). Briefly, FXIII (200 U mL−1, Fibrogammin P, CSL 
Behring, Switzerland) was activated with thrombin (2 U mL−1, Sigma–Aldrich, 
Switzerland) for 30 min at 37 °C and stored at −80 °C. Stoichiometrically balanced 
solutions of 8-PEG-Gln and 8-PEG-MMPsensitive-Lys were prepared in Tris buffer (50 mM, 
pH 7.6) and calcium chloride (50 mM). The cross-linking reaction was initiated by 
addition of 10 U mL−1 FXIIIa followed by vigorous mixing. Disc-shaped hydrogels were 
obtained by cross-linking reaction for 30 min at 37 °C. Absorbable collagen sponges (ACS, 
Lyostypt®) were shaped in discs by 3 mm biopsy punches (Kai Medical), which after 
absorption resulted in 4 mm diameter discs. 
Animals: Experiments were performed using 6-7-week-old female C57BL/6JOlaHsd. All 
animal research procedures were approved by the Animal Experimentation Committee of 
the Veterinary Office of the Canton of Zurich, Switzerland and followed the guidelines of 
the Swiss Federal Veterinary Office for the use and care of laboratory animals. 
Orthotopic bone formation in calvarial defect model: Two craniotomies (4mm 
diameter) in both parietal bones of the skull on each side of the sagittal suture were 
created. 4-weeks after craniotomy, 11µl TG-PEG hydrogel discs were pre-formed in 
presence of 0, 0.2 µg recombinant human BMP-2 (CHO cell derived, PeproTech) 
supplemented with or without 1µg recombinant murine SDF-1α (E.coli derived, 
PeproTech) and applied upon the critical-sized defects. The biomimetic hydrogel discs 
were released from one glass side and stored in humidified atmosphere until 
transplantation. Immobilization of the hydrogels upon the defects was accomplished with 
fibrin as a provisional gluing material. After craniotomy, the skin was closed with 6.0 
Vicryl sutures (Ethicon) and mice were sacrificed for ex vivo evaluations by µCT and 
histology after 8 weeks.  
Micro-CT analysis of mouse calvarial specimens: Calvaria were excised and fixed in 4% 
Formalin. µCT scans were performed in a Micro-CT40 (Scanco Medical AG) the X-ray tube 
operating at an energy of 70 kVp and an intensity of 114 μA. Three-dimensional images 
were reconstructed with an isotropic voxel size of 10 μm. A global threshold 
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corresponding to 9.8 % of the maximum grey values was used to separate bone from 
surrounding soft tissues. Regions of interest for the evaluation were selected by placing a 
cylinder of 4 mm diameter in the center of bone defects. Bone volume, connectivity, and 
trabecular thickness within this mask were measured using the ImageJ plugin BoneJ (26). 
Bone Coverage was measured in a dorso-ventral projection of the cylindrical mask. 
Histological staining and immunohistochemistry of orthotopic bone formation: 
Samples were fixed in 4% (v/v) formalin, decalcified for 10 days with 10% w/v EDTA (pH 
7.14) and embedded in paraffin. For histological evaluations, 4 μm thin tissue sections 
were stained with Hematoxylin and Eosin (H&E, Sigma-Aldrich).  
Identification of Sca1+ SSCs by fluorescence activated cell sorting (FACS): PEG-
hydrogel based cell-traps were harvested after 8 days of implantation and infiltrated cells 
were released by mechanical and enzymatic dissociation.  Specifically, the cell-traps were 
placed in collagenase A digestion buffer supplemented with DNase (Qiagen) and 
incubated at 37 °C for 40 min under gentle agitation. After collagenase digestion and 
neutralization, undigested materials were gently triturated by repeated pipetting. 
Resulting cells suspensions were filtered through 100 µm nylon mesh, pelleted at 400 g 
at 4 °C and re-suspended in FACS buffer (2% fetal bovine serum in PBS pH 7.2, 1 mM 
EDTA). Red blood cells were lysed by incubation with RBC lysis (Biolegend, cat.no 
420301) buffer for 5 min on ice before cells were washed and re-suspended in FACS 
buffer. Cells were stained with fluorochrome-conjugated antibodies against CD45 
(Biolegend, cat.no 103105), Tie2 (Biolegend, cat.no 124007), CD90.2 (Biolegend, cat.no. 
140309), 6C3 (Biolegend, cat.no. 108307) and Sca1 (Biolegend, cat.no. 108111) for 30 
min at 4 °C and analyzed by FACS. Sytox Red dead cell stain (ThermoFisher, cat.no. 
S34859) was used to evaluate cell viability, according to manufacturer recommendations. 
Flow cytometric experiments were performed with a LSR Fortessa (BD Biosciences) in 
the Flow Cytometry Core Facility, ETH Zurich. Gates were defined according to the 
fluorescence intensity of the isotype control and data was analyzed using FlowJo Software 
(FlowJo LLC). 
Statistical Analysis: All statistical analysis was performed in GraphPad Prism (GraphPad 
Software). Data analysis was executed using one-way ANOVA and post Bonferroni’s 
correction or Student’s t-test assuming two-tailed distribution and unequal variances. In 
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all cases, a p-value of <0.05 was considered statistically significant, and all data is depicted 
as mean ± SD. 
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Chapter V General discussion and future perspectives 
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General discussion 
The overall aim of this thesis was to promote bone regeneration, a unique challenge for 
both clinicians and scientists by means of tissue engineering. The focus was to establish 
cell instructive microenvironments which by allowing cell infiltration and biomolecules 
signals could be utiliz ed as sophisticated biomimetic hydrogel materials for bone 
regeneration. In the second chapter, we reported on a biomimetic cell-trap, which by 
permitting  the homing of tissue progenitor cells to bone defects was employed to further 
characterize the entrapped healing-associated cellular participants. In the third  chapter, 
a systematic in vivo approach was assumed, utilizing TG-PEG hydrogels to investigate the 
dual effect of BMP-2 and the chemokine SDF-s=  at bone healing and skeletal stem cells 
recruitment. The fourth  chapter aimed on understanding the recent identified  skeletal 
stem and progenitor cells at the microenvironment of healing fracture site. 
E                            ò biomimetic cell-trap ó  to isolate and characterize cells present 
in bone regeneration 
In the second chapter, we reported on an in vivo murine bone healing model. We aimed at 
developing a cell permissive artificial biomimetic microenvironment, which permit s 
entrapment and isolation of tissue progenitor cells that participate in bone regeneration. 
The soft PEG-                                                                  ï                           
capacity by presenting a microenvironment resembling the native wound (1). We 
demonstrated that these provisional PEG-based hydrogels encourage cell invasion and 
enable their spatial conservation. Most notably, when MMP-degradable and integrin-
binding peptide-modified PEG hydrogels niches were employed in murine calvarial 
defects, they proved to serve as cell-traps to prospectively isolate healing associated Sca1+ 
SSCs. Conclusively, this cell-trap was described as a powerful tool for investigating cellular 
events, such as migration, proliferation and differentiation occurring during bone 
regeneration.  
Identification and participation of Sca1+ SSCs in bone healing 
We reported the prospective isolation of Sca1+ SSCs directly derived from a bone wound 
microenvironment using a cell-trap approach. In vivo, we demonstrated engraftment of 
prospectively isolated, wound derived murine Sca1+ SSCs as well as their  progeny to 
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differentiate into osteoblasts and osteocytes or localize to the perivascular regions of 
sinusoids, being identified as bona fide stem cells for skeletal tissues (2). 
Biomolecule factors for bone regeneration 
A fundamental value of the tissue engineering field is to mimic the natural extracellular 
matrix and structure of the native milieu. A currently widely used approach is to 
incorporate biomolecules and various growth factors into biomaterials for controlled 
release (3). Growth factors such as BMPs and PDGF-BB have proven critical for proper 
wound repair and tissue regeneration (4, 5). Consistent with improved bone healing, we 
reported that defects treated with PDGF-BB releasing hydrogels contained significantly 
increased numbers of Sca1+ SSCs cells compared to both BMP-2 and control samples. 
These Sca1+ SSCs cells of the ventral part mostly co-localized with CD31+ endothelial cells, 
indicating their co-infiltration with vascular structures. This suggests that perivascular 
Sca1+ SSCs detected on the ventral side are crucial for bone regeneration. This is 
consistent with the current research showing that MSCs in multiple human tissues reside 
in perivascular niches (6) and that prospectively isolated CD146+ human bone marrow-
derived SSCs give rise to bone when transplanted in absence of osteogenic cues (7). 
Notably, Caplan A. recently suggested that most, if not all, MSCs arise from pericytes, 
arising a new picture to describe their positioning and functionality in situ (8). 
Accordingly, future research could be addressed by locating of MSCs to injury sites, which 
are initiated by mobilization of the circulating peripheral blood. 
Summarizing, in the second chapter we followed a stepwise bio-inspired engineering 
approach that allowed us to identify and characterize promising molecular and cellular 
key players in bone healing. We applied the knowledge gained from in vitro and in vivo 
experiments in creating cell permissive artificial biomimetic microenvironments for 
enhanced homing of Sca1+ SSCs to bone defects.  
PEG-based hydrogels, concomitant delivery of SDF- s=  “       -2, bone regeneration 
complications 
In the third chapter, we focused on a PEG-based hydrogel approach to deliver SDF-s=       
BMP-2 in order to induce bone regeneration. It has already been suggested that dual 
treatment of SDF-s=           -2 from other biomaterials such as collagen sponges (9-11), 
hyaluronic-based hydrogels (12) or silk fibroin -hydroxyapatite (13) can promote bone 
60 
 
formation. To our experience, the concomitant release of these biomolecules did not 
result in bridging the edges of bone defects.  
Different efforts to justify the failure of our system to boost bone formation were 
presented during the discussion including: i) natural scaffolds providing the appropriate 
adhesion sites directing the cellular processes during injury, ii) affinity bind sites for these 
bioactive molecules within natural scaffolds that lead to tissue formation, iii) high 
solubility of the biomolecules in vivo and rapid dispersion after implantation, and iv) 
necessity to incorporate and release of the biomolecules in a controlled manner. 
 The rapid release of SDF-1α promoted Sca1+ SSCs induction whereas; as well, fast release 
of BMP-2 facilitated significant increase of Sca1+ SSCs within the microenvironment of 
bone injury. The application of PEG-based hydrogels scaffolds may comprise a powerful 
platform in bone tissue engineering, but in respect to underlie SDF-1α, we speculate that 
the chemoattractant effect of SDF-1α was further augmented. We assumed that the fast 
release of the active biomolecule from our PEG-based hydrogel system after implantation 
resulted in rapid cell recruitment which was followed by swift degradation of our scaffold. 
Skeletal stem and progenitor cells during bone injury and regeneration 
In the fourth chapter, we focused on promoting bone healing by exploring the bone 
formation capacity of SSCs and BCSPs for the generation of novel bone healing inducing 
biomaterials. Chan and colleagues identified and introduced SSCs as cells that can 
commence progenitors, similar to the hematopoietic system. These cells are spatially 
restricted and locally resident of the bone/bone marrow organ and can generate in vivo, 
tissues associated to the skeletal system. Moreover, these skeletal stem cells are 
stimulated by BMP signaling, and instinctive to the skeletal system, when subcutaneous 
BMP-2 collagen-discs resulted in recruitment of SSCs in these matrices (14). We reported 
that biomimetic-based matrices incorporated with low-dose BMP-2 could significantly 
improve the mobilization of SSCs and BCSPs as compared to control treatments, while 
sole treatment of BMP-2 was sub-critical to promote bone regeneration. Additionally, 
transplantations of culture expanded SSCs and BCSPs to the bone-healing 
microenvironment confirmed that both cell populations maintained their ability to 
spontaneously form osteogenic cells and support the healing of critical-sized bone defects 
in presence of low-dose BMP-2.  
61 
 
These data indicate that expanded SSCs and BCSPs represent specific endogenous healing 
associated stem cell populations. Therefore, they could be highly relevant cells for the 
study of healing dynamics, cellular and molecular functions both in vitro and in vivo.  
Orthotopic healing of flat bones through endochondral ossification 
Fracture healing and bone repair are postnatal processes that resemble many of the 
developmental events taking place during embryogenesis of the skeleton and have been 
extensively reviewed (15, 16). The recapitulation of these ontological processes is 
strongly suggesting that fracture healing, which is one of the few postnatal developmental 
mechanisms, is indeed regenerative. This results in the reconstruction of the damaged 
skeletal tissue into the pre-injury cellular composition, structure and biomechanical 
function (17). 
We showed that in vicinity of healing bones of both expanded or prospectively isolated 
SSCs and BCSPs in presence of sub-critical dose of BMP-2 spontaneously differentiated 
into osteogenic cells. Careful examination of these specimen demonstrated that healing 
occurs through endochondral ossification. In contrast to the embryonic development 
where flat bones are generated though mesenchyme condensation, a process known as 
intramembranous ossification, here we show that the healing of the flat bone is at least 
partially recapitulated through the process of endochondral ossification (Figure 1). It is 
known that long bones develop through endochondral ossification with cartilaginous 
formation. During this stage chondrocytes and fibroblasts are vastly outnumbered.  
It is expected that parameters for healing are interrelated as paracrine and/or autocrine 
signaling among SSCs and their progeny and may positively regulate their own expansion, 
shifting from a stem population to a progenitor state, or participate in lineage 
specification (14) responsible to generate bone, cartilage and stromal cells within the 
wound site. 
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Figure1: Fracture repair in flat bone through endochondral ossification. Movat pentachrome stained 
sections of coronal cross sections (scale bar: 200μm). Contribution of chondrocytes in fracture repair in an 
orthotopic bone model (indicated in blue/green). Complete remodeled mineralized bone is indicated in 
yellow and stromal cells in red (inlets scale bar: 20 μm).  Resorption of cortical bone and formation of new 
woven bone were both increased in all different treatments A-C (black and red dashed line inlets) Specific 
stains the healing of flat bone (calvarial) is recapitulated rather through endochondral ossification and not 
through intramembranous ossification as during development (asterisk indicating the remaining volume of 
the used cell-trap). 
 
Sca1+ SSCs distribution within the neonatal SSC and BCSP populations 
The ideal source of stem cells for bone fracture repair should be easily accessible and cells 
should sustain viability to allow rapid in vitro culture expansion. Survival and integration 
within the host bone tissue should be enabled, while the cell source should not show 
tumorigenicity. In order to correlate Sca1+ SSCs (as described in chapter II) with the latest 
identified SSCs (facilitated in chapter IV) we explored their overlap FACS plots 
distribution within the SSCs and BCSPs populations based on surface expression markers 
by FACS (Figure 2). 
 
 
Figure2: Differential distribution of Sca1+ within SSCs and BCSPs populations by FACS 
characterization. Analysis of the differential expression of CD200 and CD105 markers, which leads to SSCs 
and their progeny in red plot, whereas in blue plot Sca1+ exhibit phenotype favoring BCSPs. Overlapping of 
these plots demonstrates only 5.8% expression of Sca1+ within the SSCs and 74.8% in BCSPs.  
 
63 
 
These results suggest that Sca1+ SSCs disseminate in favor of the progeny of SSCs 
particularly to BCSPs. Consequently, the bone nodules formation within the defects 
treated with Sca1+ SSCs could be mirrored to the ones of prospectively isolated BCSPs.  
It is worth to note that here we demonstrated the differential expression of Sca1+ cells 
secreted from neonatal limbs digestion, where previously (chapter II) the facilitated Sca1+ 
cells were wound-derived, indicating that the different source of the harvested cells could 
potentially influence their differentiation fate. Collectively, it would be essential in the 
future to investigate the potential role of wound-derived SSCs and BCSPs in bone 
regeneration, as it was reported with Sca1+ SSCs. Furthermore, we could achieve the 
comparison between wound-derived Sca1+ SSCs and wound-derived SSCs and BCSPs. 
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Future Perspectives 
Most adult stem cells are suggested to be quiescent and reside in a specialized 
microenvironment, which is termed as “stem cell niche” (18).  The stem cell niche 
hypothesis provided an initial core in which the cell types and factors involved in 
determining stem cell behavior is still to be defined. Advancements in techniques such as 
lineage-tracing, single cell isolation, manipulation and imaging will broaden our 
knowledge in the nature of stem cell niche-cell interactions (19). These stem cells are 
activated after tissue injury and participate in the healing process. In addition, bone 
marrow-derived stem cells have been identified as crucial cell sources with regenerative 
capacity that could contribute to other tissues. The bone marrow pools home 
stem/progenitor cells that contains niches for hematopoietic stem cells (HSCs), 
mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs). HSCs are 
regulating the secretion of all circulating blood cells. A crucial aspect of the HSC 
population for tissue regeneration is to support with paracrine bioactive factors to cells 
with regenerative capacities and further differentiate into desired tissue-specific lineages 
(20).  Up to now, the origin of stem/progenitor cells within the bone wound remains a 
question as well as their way of accessing the wound.  
In this thesis, with the objective of bone repair in a manner which recapitulates natural 
bone healing process, both cell-based (Chapter II and IV) and free strategies (Chapter II 
and III) have been employed. Both showed to be advantageous, but currently cell-based 
therapeutic approaches are the status quo in pre-clinical applications. We believe that 
future research should be directed towards investigating cellular processes of MSCs and 
SSCs / BCSPs injury-derived, such as migration, induction, proliferation and 
differentiation in order to elucidate their role in bone healing. Future implants should 
therefore be designed such that they first release a chemoattractant that recruits healing-
associated stem and progenitor cells, second deliver a mitogen stimulus to promote cell 
proliferation and third exert osteogenic cues to induce differentiation.  
While the perfect biomimetic scaffold does not currently exist, constant advancements in 
tissue engineering research have resulted in increasing numbers of commercially 
available products and promising future therapies. As research in regenerative medicine 
continues to grow, we envision novel scaffold technology, which includes autologous “off 
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the shelf” cell-based scaffolds and combination of established strategies involving stem 
cells, gene therapy, small biomolecules, and mechanical forces. We believe that the 
application of a biomaterial-based cell-trap presented herein, is an appealing approach 
for reducing the number of isolated stem or progenitor cells participating in bone 
regeneration in order to be applied in vivo in a healing fracture site. Due to its synthetic 
and bioinert nature the presented biomimetic cell-trap allows the occurrence of the 
natural healing cascade, which is essential for the creation of more efficient clinically safe 
bone healing implants. We see a tremendous clinical potential for smart cell-instructive 
implants that aim at substituting or accelerating naturally occurring signals to enhance 
the healing process in deficient tissues. 
The engineering of systems that specifically control biological processes by 
spatiotemporally controlling the release of multiple factors will enable the study of 
healing mechanism and the design of next generation smart healing materials. The herein 
used synthetic material allows the study of the natural healing cascade in absence of 
uncontrollable confounding signals present in naturally derived biomaterials. Moreover, 
by tailoring the “cell-trap” degradation rate to the natural healing cascade the spatial 
distribution of elements participating in bone healing can be conserved. With respect to 
the here intended manipulation of SSCs participating in bone regeneration, precisely 
balancing their migration, proliferation and differentiation will be essential. To fully 
exploit the body's healing capacity, selected elements of the natural extracellular matrix 
such as engineered integrin binding sites acting synergistically with adjacent to growth 
factor binding sites will be crucial (5). Besides, another point of consideration is the 
release kinetics in vivo of bioactive molecules.  While in vitro release profiles have been 
evaluated (5, 21), in vivo release kinetics remains unknown. Furthermore, the potential 
cross-talks influenced by doses, release kinetics and release sequence of growth factors 
during combined treatments (22) have not been determined. Finally, the correlation 
between the here reported murine SSCs and human healing associated SSCs will be 
important for the creation of customized artificial microenvironments that augment the 
natural healing cascade, in order to be employed in defected sites for in situ tissue 
engineering applications.  
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